EXEL, VRNA, ALKS, KNSA, and IMCR are gaining ground as biotech M&A heats up and innovation offsets macro uncertainty.

But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. Everyone has their own methods for finding great value opportunities, but our ...

Alkermes has said it is considering a spin-out of its cancer business into an independent, publicly-traded company, retaining its traditional focus on neurosciences. The Ireland-domiciled company ...

View the latest Alkermes PLC (ALKS) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Alkermes has agreed a $950 million deal to acquire Rodin Therapeutics, a US biotech developing drugs for neurodegenerative diseases. Dublin-headquartered Alkermes is paying $100 million upfront to ...

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. When it comes to biotech ETFs, ...

Deutsche Bank this week updated its Fresh Money Quarterly list, spotlighting top investment ideas to hold over the next year ...